{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T22:47:37Z","timestamp":1793659657461,"version":"4.5.1"},"reference-count":184,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T00:00:00Z","timestamp":1762732800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T00:00:00Z","timestamp":1762732800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100004735","name":"Natural Science Foundation of Hunan Province","doi-asserted-by":"publisher","award":["2024JJ9264"],"award-info":[{"award-number":["2024JJ9264"]}],"id":[{"id":"10.13039\/501100004735","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004735","name":"Natural Science Foundation of Hunan Province","doi-asserted-by":"publisher","award":["2023JJ60468"],"award-info":[{"award-number":["2023JJ60468"]}],"id":[{"id":"10.13039\/501100004735","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004735","name":"Natural Science Foundation of Hunan Province","doi-asserted-by":"publisher","award":["2024JJ2039"],"award-info":[{"award-number":["2024JJ2039"]}],"id":[{"id":"10.13039\/501100004735","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004735","name":"Natural Science Foundation of Hunan Province","doi-asserted-by":"publisher","award":["2024JJ8117"],"award-info":[{"award-number":["2024JJ8117"]}],"id":[{"id":"10.13039\/501100004735","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002767","name":"Department of Science and Technology of Hunan Province","doi-asserted-by":"publisher","award":["2023ZJ1120"],"award-info":[{"award-number":["2023ZJ1120"]}],"id":[{"id":"10.13039\/501100002767","id-type":"DOI","asserted-by":"publisher"}]},{"name":"High-Level Talent Support Program of Hunan Cancer Hospital","award":["20250730-1011"],"award-info":[{"award-number":["20250730-1011"]}]},{"name":"High-Level Talent Support Program of Hunan Cancer Hospital","award":["20250731-1015"],"award-info":[{"award-number":["20250731-1015"]}]},{"DOI":"10.13039\/100017695","name":"Health Commission of Hunan Province","doi-asserted-by":"publisher","award":["20230355"],"award-info":[{"award-number":["20230355"]}],"id":[{"id":"10.13039\/100017695","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["Grant No. 82273466"],"award-info":[{"award-number":["Grant No. 82273466"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Hunan Cancer Hospital Climb Plan","award":["ZX2021002"],"award-info":[{"award-number":["ZX2021002"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Cancer"],"DOI":"10.1186\/s12943-025-02487-4","type":"journal-article","created":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T13:32:55Z","timestamp":1762781575000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Neoadjuvant immunotherapy in squamous cell carcinoma of the head and neck: current evidence and future perspectives"],"prefix":"10.1186","volume":"24","author":[{"given":"Bocheng","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haolei","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingyu","family":"Kuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shixuan","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Pang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Ouyang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hailin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,10]]},"reference":[{"key":"2487_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229\u201363. https:\/\/doi.org\/10.3322\/caac.21834.","journal-title":"CA Cancer J Clin"},{"key":"2487_CR2","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1002\/cncr.32539","volume":"126","author":"S Gulati","year":"2019","unstructured":"Gulati S, Desai J, Palackdharry SM, Morris JC, Zhu Z, Jandarov R, et al. Phase 1 dose-finding study of Metformin in combination with concurrent cisplatin and radiotherapy in patients with locally advanced head and neck squamous cell cancer. Cancer. 2019;126:354\u201362. https:\/\/doi.org\/10.1002\/cncr.32539.","journal-title":"Cancer"},{"key":"2487_CR3","doi-asserted-by":"publisher","first-page":"2815","DOI":"10.1200\/JCO.2010.32.4103","volume":"29","author":"M Henke","year":"2011","unstructured":"Henke M, Alfonsi M, Foa P, Giralt J, Bardet E, Cerezo L, et al. Palifermin decreases severe oral mucositis of patients undergoing postoperative radiochemotherapy for head and neck cancer: a randomized, placebo-controlled trial. J Clin Oncol. 2011;29:2815\u201320. https:\/\/doi.org\/10.1200\/JCO.2010.32.4103.","journal-title":"J Clin Oncol"},{"key":"2487_CR4","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1007\/s11912-012-0216-1","volume":"14","author":"KA Hutcheson","year":"2012","unstructured":"Hutcheson KA, Lewin JS. Functional outcomes after chemoradiotherapy of laryngeal and pharyngeal cancers. Curr Oncol Rep. 2012;14:158\u201365. https:\/\/doi.org\/10.1007\/s11912-012-0216-1.","journal-title":"Curr Oncol Rep"},{"key":"2487_CR5","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1016\/j.ijrobp.2009.01.058","volume":"76","author":"L Lambert","year":"2010","unstructured":"Lambert L, Fortin B, Souli\u00e8res D, Guertin L, Coulombe G, Charpentier D, et al. Organ preservation with concurrent chemoradiation for advanced laryngeal cancer: are we succeeding? Int J Radiat Oncol. 2010;76:398\u2013402. https:\/\/doi.org\/10.1016\/j.ijrobp.2009.01.058.","journal-title":"Int J Radiat Oncol"},{"key":"2487_CR6","doi-asserted-by":"publisher","first-page":"7539","DOI":"10.1158\/1078-0432.CCR-11-2102","volume":"17","author":"ABY Hui","year":"2011","unstructured":"Hui ABY, Bruce JP, Alajez NM, Shi W, Yue S, Perez-Ordonez B, et al. Significance of dysregulated Metadherin and microRNA-375 in head and neck cancer. Clin Cancer Res. 2011;17:7539\u201350. https:\/\/doi.org\/10.1158\/1078-0432.CCR-11-2102.","journal-title":"Clin Cancer Res"},{"key":"2487_CR7","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1158\/1078-0432.CCR-17-1261","volume":"24","author":"TL Whiteside","year":"2018","unstructured":"Whiteside TL. Head and neck carcinoma immunotherapy: facts and hopes. Clin Cancer Res. 2018;24:6\u201313. https:\/\/doi.org\/10.1158\/1078-0432.CCR-17-1261.","journal-title":"Clin Cancer Res"},{"key":"2487_CR8","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.ctrv.2018.03.003","volume":"65","author":"S Cavalieri","year":"2018","unstructured":"Cavalieri S, Rivoltini L, Bergamini C, Locati LD, Licitra L, Bossi P. Immuno-oncology in head and neck squamous cell cancers: news from clinical trials, emerging predictive factors and unmet needs. Cancer Treat Rev. 2018;65:78\u201386. https:\/\/doi.org\/10.1016\/j.ctrv.2018.03.003.","journal-title":"Cancer Treat Rev"},{"key":"2487_CR9","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1200\/JCO.2003.06.146","volume":"21","author":"L Licitra","year":"2003","unstructured":"Licitra L, Grandi C, Guzzo M, Mariani L, Lo Vullo S, Valvo F, et al. Primary chemotherapy in resectable oral cavity squamous cell cancer: a randomized controlled trial. J Clin Oncol. 2003;21:327\u201333. https:\/\/doi.org\/10.1200\/JCO.2003.06.146.","journal-title":"J Clin Oncol"},{"key":"2487_CR10","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1200\/JCO.2012.43.8820","volume":"31","author":"L Zhong","year":"2013","unstructured":"Zhong L, Zhang C, Ren G, Guo W, William WN, Sun J, et al. Randomized phase III trial of induction chemotherapy with docetaxel, cisplatin, and fluorouracil followed by surgery versus up-front surgery in locally advanced resectable oral squamous cell carcinoma. J Clin Oncol. 2013;31:744\u201351. https:\/\/doi.org\/10.1200\/JCO.2012.43.8820.","journal-title":"J Clin Oncol"},{"key":"2487_CR11","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1200\/JCO.21.00179","volume":"40","author":"D Chaukar","year":"2022","unstructured":"Chaukar D, Prabash K, Rane P, Patil VM, Thiagarajan S, Ghosh-Laskar S, et al. Prospective phase II open-label randomized controlled trial to compare mandibular preservation in upfront surgery with neoadjuvant chemotherapy followed by surgery in operable oral cavity cancer. J Clin Oncol. 2022;40:272\u201381. https:\/\/doi.org\/10.1200\/JCO.21.00179.","journal-title":"J Clin Oncol"},{"key":"2487_CR12","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/j.ccell.2018.03.008","volume":"33","author":"RH Vonderheide","year":"2018","unstructured":"Vonderheide RH. The immune revolution: a case for priming, not checkpoint. Cancer Cell. 2018;33:563\u20139. https:\/\/doi.org\/10.1016\/j.ccell.2018.03.008.","journal-title":"Cancer Cell"},{"key":"2487_CR13","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1126\/science.aar4060","volume":"359","author":"A Ribas","year":"2018","unstructured":"Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. Science. 2018;359:1350\u20135. https:\/\/doi.org\/10.1126\/science.aar4060.","journal-title":"Science"},{"key":"2487_CR14","doi-asserted-by":"publisher","first-page":"4828","DOI":"10.1200\/JCO.2011.38.0899","volume":"29","author":"SL Topalian","year":"2011","unstructured":"Topalian SL, Weiner GJ, Pardoll DM. Cancer immunotherapy comes of age. J Clin Oncol. 2011;29:4828\u201336. https:\/\/doi.org\/10.1200\/JCO.2011.38.0899.","journal-title":"J Clin Oncol"},{"key":"2487_CR15","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-002256","volume":"9","author":"E Lauret Marie Joseph","year":"2021","unstructured":"Lauret Marie Joseph E, Kirilovsky A, Lecoester B, El Sissy C, Boullerot L, Rangan L, et al. Chemoradiation triggers antitumor Th1 and tissue resident memory-polarized immune responses to improve immune checkpoint inhibitors therapy. J Immunother Cancer. 2021;9:e002256. https:\/\/doi.org\/10.1136\/jitc-2020-002256.","journal-title":"J Immunother Cancer"},{"key":"2487_CR16","doi-asserted-by":"publisher","unstructured":"Uppaluri R, Campbell KM, Egloff AM, et al. Neoadjuvant and adjuvant pembrolizumab in resectable locally advanced, human papillomavirus-unrelated head and neck cancer: a multicenter, phase II trial. Clin Cancer Res. 2020;26(19):5140\u201352. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-1695.","DOI":"10.1158\/1078-0432.CCR-20-1695"},{"key":"2487_CR17","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002568","volume":"9","author":"RL Ferris","year":"2021","unstructured":"Ferris RL, Spanos WC, Leidner R, Gon\u00e7alves A, Martens UM, Kyi C, et al. Neoadjuvant nivolumab for patients with resectable HPV-positive and HPV-negative squamous cell carcinomas of the head and neck in the CheckMate 358 trial. J Immunother Cancer. 2021;9:e002568. https:\/\/doi.org\/10.1136\/jitc-2021-002568.","journal-title":"J Immunother Cancer"},{"key":"2487_CR18","doi-asserted-by":"publisher","first-page":"3211","DOI":"10.1158\/1078-0432.CCR-19-3977","volume":"26","author":"R Ferrarotto","year":"2020","unstructured":"Ferrarotto R, Bell D, Rubin ML, Hutcheson KA, Johnson JM, Goepfert RP, et al. Impact of neoadjuvant durvalumab with or without tremelimumab on CD8\u2009+\u2009tumor lymphocyte density, safety, and efficacy in patients with oropharynx cancer: CIAO trial results. Clin Cancer Res. 2020;26:3211\u20139. https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-3977.","journal-title":"Clin Cancer Res"},{"key":"2487_CR19","doi-asserted-by":"publisher","first-page":"S1169","DOI":"10.1016\/j.annonc.2020.08.2270","volume":"31","author":"L Zuur","year":"2020","unstructured":"Zuur L, Vos JL, Elbers JB, Krijgsman O, Qiao X, van der Leun A, et al. LBA40 Neoadjuvant nivolumab and nivolumab plus ipilimumab induce (near-) complete responses in patients with head and neck squamous cell carcinoma: The IMCISION trial. Ann Oncol. 2020;31:S1169-9. https:\/\/doi.org\/10.1016\/j.annonc.2020.08.2270.","journal-title":"Ann Oncol"},{"key":"2487_CR20","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1007\/s40487-023-00226-7","volume":"11","author":"S Zheng","year":"2023","unstructured":"Zheng S, Feng Y, Li C, Zhang J, Xie K. Induction therapy for locally advanced head and neck squamous cell carcinoma. Oncol Ther. 2023;11:185\u201398. https:\/\/doi.org\/10.1007\/s40487-023-00226-7.","journal-title":"Oncol Ther"},{"key":"2487_CR21","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1269863","volume":"14","author":"H Wang","year":"2023","unstructured":"Wang H, Zheng Z, Zhang Y, Bian C, Bao J, Xin Y, et al. Locally advanced head and neck squamous cell carcinoma treatment efficacy and safety: a systematic review and network meta-analysis. Front Pharmacol. 2023;14:1269863. https:\/\/doi.org\/10.3389\/fphar.2023.1269863.","journal-title":"Front Pharmacol"},{"key":"2487_CR22","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1007\/s12094-020-02447-y","volume":"23","author":"S Mollnar","year":"2020","unstructured":"Mollnar S, Pondorfer P, Kasparek A-K, Reinisch S, Moik F, Stotz M, et al. Decrease in treatment intensity predicts worse outcome in patients with locally advanced head and neck squamous cell carcinoma undergoing radiochemotherapy. Clin Transl Oncol. 2020;23:543\u201353. https:\/\/doi.org\/10.1007\/s12094-020-02447-y.","journal-title":"Clin Transl Oncol"},{"key":"2487_CR23","doi-asserted-by":"publisher","first-page":"11234","DOI":"10.1002\/cam4.5815","volume":"12","author":"U Nindra","year":"2023","unstructured":"Nindra U, Hurwitz J, Forstner D, Chin V, Gallagher R, Liu J. A systematic review of neoadjuvant and definitive immunotherapy in locally advanced head and neck squamous cell carcinoma. Cancer Med. 2023;12:11234\u201347. https:\/\/doi.org\/10.1002\/cam4.5815.","journal-title":"Cancer Med"},{"key":"2487_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2025.107598","volume":"212","author":"X Zhu","year":"2025","unstructured":"Zhu X, Qiu J, Zhang Y, Lin C, Wang X, Shi X, et al. Neoadjuvant chemoimmunotherapy for locally advanced squamous cell carcinoma of the head and neck: systematic review and meta-analysis. Pharmacol Res. 2025;212:107598. https:\/\/doi.org\/10.1016\/j.phrs.2025.107598.","journal-title":"Pharmacol Res"},{"issue":"5","key":"2487_CR25","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2025.0081","volume":"11","author":"AJ Rosenberg","year":"2025","unstructured":"Rosenberg AJ, Juloori A, Jelinek MJ, Agrawal N, Cursio JF, Cipriani N, et al. Neoadjuvant nivolumab plus chemotherapy followed by response-stratified chemoradiation therapy in HPV-negative head and neck cancer: the DEPEND phase 2 nonrandomized clinical trial. JAMA Oncol. 2025;e250081. https:\/\/doi.org\/10.1001\/jamaoncol.2025.0081.","journal-title":"JAMA Oncol"},{"key":"2487_CR26","doi-asserted-by":"publisher","first-page":"e37","DOI":"10.6004\/jnccn.2015.0080","volume":"13","author":"AD Colevas","year":"2015","unstructured":"Colevas AD. Systemic therapy for metastatic or recurrent squamous cell carcinoma of the head and neck. J Natl Compr Canc Netw. 2015;13:e37\u201348. https:\/\/doi.org\/10.6004\/jnccn.2015.0080.","journal-title":"J Natl Compr Canc Netw"},{"key":"2487_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2024.113560","volume":"200","author":"V Noronha","year":"2024","unstructured":"Noronha V, Patil V, Chaturvedi P, Mathrudev V, Menon N, Bhattacharjee A, et al. Phase 3 RCT comparing docetaxel-platinum with docetaxel-platinum-5FU as neoadjuvant chemotherapy in borderline resectable oral cancer. Eur J Cancer. 2024;200:113560. https:\/\/doi.org\/10.1016\/j.ejca.2024.113560.","journal-title":"Eur J Cancer"},{"key":"2487_CR28","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003026","volume":"10","author":"RI Haddad","year":"2022","unstructured":"Haddad RI, Seiwert TY, Chow LQM, Gupta S, Weiss J, Gluck I, et al. Influence of tumor mutational burden, inflammatory gene expression profile, and PD-L1 expression on response to pembrolizumab in head and neck squamous cell carcinoma. J Immunother Cancer. 2022;10:e003026. https:\/\/doi.org\/10.1136\/jitc-2021-003026.","journal-title":"J Immunother Cancer"},{"key":"2487_CR29","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1016\/S1470-2045(17)30421-7","volume":"18","author":"KJ Harrington","year":"2017","unstructured":"Harrington KJ, Ferris RL, Blumenschein G, Colevas AD, Fayette J, Licitra L, et al. Nivolumab versus standard, single-agent therapy of investigator\u2019s choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial. Lancet Oncol. 2017;18:1104\u201315. https:\/\/doi.org\/10.1016\/S1470-2045(17)30421-7.","journal-title":"Lancet Oncol"},{"key":"2487_CR30","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/S0140-6736(18)31999-8","volume":"393","author":"EEW Cohen","year":"2019","unstructured":"Cohen EEW, Souli\u00e8res D, Le Tourneau C, Dinis J, Licitra L, Ahn M-J, et al. Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study. Lancet. 2019;393:156\u201367. https:\/\/doi.org\/10.1016\/S0140-6736(18)31999-8.","journal-title":"Lancet"},{"key":"2487_CR31","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1016\/S0140-6736(19)32591-7","volume":"394","author":"B Burtness","year":"2019","unstructured":"Burtness B, Harrington KJ, Greil R, Souli\u00e8res D, Tahara M, de Castro G, et al. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet. 2019;394:1915\u201328. https:\/\/doi.org\/10.1016\/S0140-6736(19)32591-7.","journal-title":"Lancet"},{"key":"2487_CR32","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1016\/j.annonc.2020.04.001","volume":"31","author":"RL Ferris","year":"2020","unstructured":"Ferris RL, Haddad R, Even C, Tahara M, Dvorkin M, Ciuleanu TE, et al. Durvalumab with or without tremelimumab in patients with recurrent or metastatic head and neck squamous cell carcinoma: EAGLE, a randomized, open-label phase III study. Ann Oncol. 2020;31:942\u201350. https:\/\/doi.org\/10.1016\/j.annonc.2020.04.001.","journal-title":"Ann Oncol"},{"issue":"16suppl","key":"2487_CR33","doi-asserted-by":"publisher","first-page":"6018","DOI":"10.1200\/JCO.2023.41.16_suppl.6018","volume":"41","author":"RL Ferris","year":"2023","unstructured":"Ferris RL, Gooding WE, Chiosea SI, et al. Neoadjuvant nivolumab alone or in combination with relatlimab or ipilimumab in resectable head and neck squamous cell carcinoma (HNSCC) [J]. J Clin Oncol. 2023;41(16suppl):6018. https:\/\/doi.org\/10.1200\/JCO.2023.41.16_suppl.6018.","journal-title":"J Clin Oncol"},{"key":"2487_CR34","doi-asserted-by":"publisher","first-page":"5140","DOI":"10.1158\/1078-0432.CCR-20-1695","volume":"26","author":"R Uppaluri","year":"2020","unstructured":"Uppaluri R, Campbell KM, Egloff AM, Zolkind P, Skidmore ZL, Nussenbaum B, et al. Neoadjuvant and adjuvant pembrolizumab in resectable locally advanced, human papillomavirus\u2013unrelated head and neck cancer: a multicenter, phase II trial. Clin Cancer Res. 2020;26:5140\u201352. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-1695.","journal-title":"Clin Cancer Res"},{"issue":"10","key":"2487_CR35","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1001\/jamaoto.2021.2191","volume":"147","author":"R Masarwy","year":"2021","unstructured":"Masarwy R, Kampel L, Horowitz G, Gutfeld O, Muhanna N. Neoadjuvant PD-1\/PD-L1 inhibitors for resectable head and neck cancer: a systematic review and meta-analysis. JAMA Otolaryngol Head Neck Surg. 2021;147:871. https:\/\/doi.org\/10.1001\/jamaoto.2021.2191.","journal-title":"JAMA Otolaryngol Head Neck Surg"},{"key":"2487_CR36","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1002\/hed.26601","volume":"43","author":"AC Mays","year":"2021","unstructured":"Mays AC, Yarlagadda B, Achim V, Jackson R, Pipkorn P, Huang AT, et al. Examining the relationship of immunotherapy and wound complications following flap reconstruction in patients with head and neck cancer. Head Neck. 2021;43:1509\u201320. https:\/\/doi.org\/10.1002\/hed.26601.","journal-title":"Head Neck"},{"key":"2487_CR37","doi-asserted-by":"publisher","first-page":"6006","DOI":"10.1200\/JCO.2021.39.15_suppl.6006","volume":"39","author":"TM Wise-Draper","year":"2021","unstructured":"Wise-Draper TM, Takiar V, Mierzwa ML, Casper K, Palackdharry S, Worden FP, et al. Association of pathological response to neoadjuvant pembrolizumab with tumor PD-L1 expression and high disease-free survival (DFS) in patients with resectable, local-regionally advanced, head and neck squamous cell carcinoma (HNSCC). J Clin Oncol. 2021;39:6006\u20136006. https:\/\/doi.org\/10.1200\/JCO.2021.39.15_suppl.6006.","journal-title":"J Clin Oncol"},{"key":"2487_CR38","doi-asserted-by":"publisher","unstructured":"Bernier J, Domenge C, Ozsahin M, Matuszewska K, Lef\u00e8bvre JL, Greiner RH, et al. European organization for research and treatment of cancer trial 22931. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med. 2004;350(19):1945\u201352. https:\/\/doi.org\/10.1056\/NEJMoa032641.","DOI":"10.1056\/NEJMoa032641"},{"key":"2487_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2021.100426","volume":"2","author":"HM Knochelmann","year":"2021","unstructured":"Knochelmann HM, Horton JD, Liu S, Armeson K, Kaczmar JM, Wyatt MM, et al. Neoadjuvant presurgical PD-1 inhibition in oral cavity squamous cell carcinoma. Cell Rep Med. 2021;2:100426. https:\/\/doi.org\/10.1016\/j.xcrm.2021.100426.","journal-title":"Cell Rep Med"},{"key":"2487_CR40","doi-asserted-by":"publisher","first-page":"899","DOI":"10.6004\/jnccn.2020.7590","volume":"18","author":"X Le","year":"2020","unstructured":"Le X, Ferrarotto R, Wise-Draper T, Gillison M. Evolving role of immunotherapy in recurrent metastatic head and neck cancer. J Natl Compr Canc Netw. 2020;18:899\u2013906. https:\/\/doi.org\/10.6004\/jnccn.2020.7590.","journal-title":"J Natl Compr Canc Netw"},{"key":"2487_CR41","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1038\/s41571-019-0227-z","volume":"16","author":"JD Cramer","year":"2019","unstructured":"Cramer JD, Burtness B, Le QT, Ferris RL. The changing therapeutic landscape of head and neck cancer. Nat Rev Clin Oncol. 2019;16:669\u201383. https:\/\/doi.org\/10.1038\/s41571-019-0227-z.","journal-title":"Nat Rev Clin Oncol"},{"key":"2487_CR42","doi-asserted-by":"publisher","first-page":"907","DOI":"10.6004\/jnccn.2020.7594","volume":"18","author":"HN Vasudevan","year":"2020","unstructured":"Vasudevan HN, Yom SS. Combining systemic therapy with radiation: head and neck cancer treatments in an era of targeted agents and immunotherapy. J Natl Compr Canc Netw. 2020;18:907\u201313. https:\/\/doi.org\/10.6004\/jnccn.2020.7594.","journal-title":"J Natl Compr Canc Netw"},{"key":"2487_CR43","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-26472-9","volume":"12","author":"JL Vos","year":"2021","unstructured":"Vos JL, Elbers JBW, Krijgsman O, Traets JJH, Qiao X, Van Der Leun AM, et al. Neoadjuvant immunotherapy with nivolumab and ipilimumab induces major pathological responses in patients with head and neck squamous cell carcinoma. Nat Commun. 2021;12:7348. https:\/\/doi.org\/10.1038\/s41467-021-26472-9.","journal-title":"Nat Commun"},{"key":"2487_CR44","doi-asserted-by":"publisher","unstructured":"Cha J, Kim DH, Kim G, et al. Single-cell analysis reveals cellular and molecular factors counteracting HPV-positive oropharyngeal cancer immunotherapy outcomes. J Immunother Cancer. 2024;12(6):e008667. https:\/\/doi.org\/10.1136\/jitc-2023-008667.","DOI":"10.1136\/jitc-2023-008667"},{"key":"2487_CR45","doi-asserted-by":"publisher","first-page":"4557","DOI":"10.1158\/1078-0432.CCR-21-0585","volume":"27","author":"R Ferrarotto","year":"2021","unstructured":"Ferrarotto R, Amit M, Nagarajan P, Rubin ML, Yuan Y, Bell D, et al. Pilot phase II trial of neoadjuvant immunotherapy in locoregionally Advanced, resectable cutaneous squamous cell carcinoma of the head and neck. Clin Cancer Res. 2021;27:4557\u201365. https:\/\/doi.org\/10.1158\/1078-0432.CCR-21-0585.","journal-title":"Clin Cancer Res"},{"key":"2487_CR46","doi-asserted-by":"publisher","first-page":"2918","DOI":"10.1016\/j.cell.2022.06.018","volume":"185","author":"AM Luoma","year":"2022","unstructured":"Luoma AM, Suo S, Wang Y, Gunasti L, Porter CBM, Nabilsi N, et al. Tissue-resident memory and Circulating T cells are early responders to pre-surgical cancer immunotherapy. Cell. 2022;185:2918\u2013e293529. https:\/\/doi.org\/10.1016\/j.cell.2022.06.018.","journal-title":"Cell"},{"key":"2487_CR47","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-33080-8","volume":"13","author":"W-T Ju","year":"2022","unstructured":"Ju W-T, Xia R-H, Zhu D-W, Dou S-J, Zhu G-P, Dong M-J, et al. A pilot study of neoadjuvant combination of anti-PD-1 camrelizumab and VEGFR2 inhibitor apatinib for locally advanced resectable oral squamous cell carcinoma. Nat Commun. 2022;13:5378. https:\/\/doi.org\/10.1038\/s41467-022-33080-8.","journal-title":"Nat Commun"},{"key":"2487_CR48","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1016\/j.cell.2023.02.021","volume":"186","author":"MK Rahim","year":"2023","unstructured":"Rahim MK, Okholm TLH, Jones KB, McCarthy EE, Liu CC, Yee JL, et al. Dynamic CD8\u2009+\u2009T cell responses to cancer immunotherapy in human regional lymph nodes are disrupted in metastatic lymph nodes. Cell. 2023;186:1127\u2013e114318. https:\/\/doi.org\/10.1016\/j.cell.2023.02.021.","journal-title":"Cell"},{"key":"2487_CR49","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001378","volume":"8","author":"M Hecht","year":"2020","unstructured":"Hecht M, Gostian AO, Eckstein M, Rutzner S, von der Gr\u00fcn J, Illmer T, et al. Safety and efficacy of single cycle induction treatment with cisplatin\/docetaxel\/ durvalumab\/tremelimumab in locally advanced HNSCC: first results of CheckRad-CD8. J Immunother Cancer. 2020;8:e001378. https:\/\/doi.org\/10.1136\/jitc-2020-001378.","journal-title":"J Immunother Cancer"},{"key":"2487_CR50","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-022-02510-2","volume":"41","author":"X Huang","year":"2022","unstructured":"Huang X, Liu Q, Zhong G, Peng Y, Liu Y, Liang L, et al. Neoadjuvant Toripalimab combined with gemcitabine and cisplatin in resectable locally advanced head and neck squamous cell carcinoma (NeoTGP01): an open label, single-arm, phase Ib clinical trial. J Exp Clin Cancer Res. 2022;41:300. https:\/\/doi.org\/10.1186\/s13046-022-02510-2.","journal-title":"J Exp Clin Cancer Res"},{"key":"2487_CR51","doi-asserted-by":"publisher","first-page":"106918","DOI":"10.1016\/j.oraloncology.2024.106918","volume":"156","author":"X Zhao","year":"2024","unstructured":"Zhao X, Zhou Y, Peng G, Wen L, Hong X, Hu Y, et al. Final analysis of a phase II trial of neoadjuvant chemoimmunotherapy for locoregionally advanced head and neck squamous cell carcinoma. Oral Oncol. 2024;156:106918. https:\/\/doi.org\/10.1016\/j.oraloncology.2024.106918.","journal-title":"Oral Oncol"},{"key":"2487_CR52","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1189752","volume":"14","author":"K Wang","year":"2023","unstructured":"Wang K, Gui L, Lu H, He X, Li D, Liu C, et al. Efficacy and safety of pembrolizumab with preoperative neoadjuvant chemotherapy in patients with resectable locally advanced head and neck squamous cell carcinomas. Front Immunol. 2023;14:1189752. https:\/\/doi.org\/10.3389\/fimmu.2023.1189752.","journal-title":"Front Immunol"},{"key":"2487_CR53","doi-asserted-by":"publisher","first-page":"S571","DOI":"10.1016\/j.annonc.2023.09.2040","volume":"34","author":"H Wang","year":"2023","unstructured":"Wang H, Wang X, Zhou X, Li Y, Wang P, Zhang X, et al. Neoadjuvant PD-1 inhibitor combined with Nab-paclitaxel and cisplatin in resectable locally advanced head and neck squamous cell carcinoma (NCT05522985): A randomized, controlled, open label, phase II clinical trial. Ann Oncol. 2023;34:S571\u20132. https:\/\/doi.org\/10.1016\/j.annonc.2023.09.2040.","journal-title":"Ann Oncol"},{"key":"2487_CR54","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1467306","volume":"15","author":"C Liu","year":"2024","unstructured":"Liu C, Li M, Liu X, Shi T, Wang Y, Sui C, et al. Evaluating the efficacy and safety of different neoadjuvant immunotherapy combinations in locally advanced HNSCC: a systematic review and meta-analysis. Front Immunol. 2024;15:1467306. https:\/\/doi.org\/10.3389\/fimmu.2024.1467306.","journal-title":"Front Immunol"},{"key":"2487_CR55","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002485","volume":"9","author":"R Leidner","year":"2021","unstructured":"Leidner R, Crittenden M, Young K, Xiao H, Wu Y, Couey MA, et al. Neoadjuvant immunoradiotherapy results in high rate of complete pathological response and clinical to pathological downstaging in locally advanced head and neck squamous cell carcinoma. J Immunother Cancer. 2021;9:e002485. https:\/\/doi.org\/10.1136\/jitc-2021-002485.","journal-title":"J Immunother Cancer"},{"key":"2487_CR56","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1038\/s43018-022-00450-6","volume":"3","author":"LB Darragh","year":"2022","unstructured":"Darragh LB, Knitz MM, Hu J, Clambey ET, Backus J, Dumit A, et al. A phase I\/Ib trial and biological correlate analysis of neoadjuvant SBRT with single-dose durvalumab in HPV-unrelated locally advanced HNSCC. Nat Cancer. 2022;3:1300\u201317. https:\/\/doi.org\/10.1038\/s43018-022-00450-6.","journal-title":"Nat Cancer"},{"key":"2487_CR57","doi-asserted-by":"publisher","first-page":"e007141","DOI":"10.1136\/jitc-2023-007141","volume":"11","author":"J Jm","year":"2023","unstructured":"Jm J, Ia V, La H, V AA. Nivolumab and ipilimumab in combination with radiotherapy in patients with high-risk locally advanced squamous cell carcinoma of the head and neck. J Immunother Cancer. 2023;11:e007141. https:\/\/doi.org\/10.1136\/jitc-2023-007141.","journal-title":"J Immunother Cancer"},{"key":"2487_CR58","doi-asserted-by":"publisher","DOI":"10.1172\/JCI161400","volume":"132","author":"JM Redman","year":"2022","unstructured":"Redman JM, Friedman J, Robbins Y, Sievers C, Yang X, Lassoued W, et al. Enhanced neoepitope-specific immunity following neoadjuvant PD-L1 and TGF-\u03b2 blockade in HPV-unrelated head and neck cancer. J Clin Invest. 2022;132:e161400. https:\/\/doi.org\/10.1172\/JCI161400.","journal-title":"J Clin Invest"},{"issue":"16suppl","key":"2487_CR59","doi-asserted-by":"publisher","first-page":"6019","DOI":"10.1200\/JCO","volume":"41","author":"W Wong","year":"2023","unstructured":"Wong W, Cracchiolo JR, Riaz N, et al. Neoadjuvant Cemiplimab with platinum-doublet chemotherapy and cetuximab to de\u2010escalate surgery and omit adjuvant radiation in locoregionally advanced head & neck squamous cell carcinoma (HNSCC) [J]. J Clin Oncol. 2023;41(16suppl):6019. https:\/\/doi.org\/10.1200\/JCO. 2023.41.16_ suppl.6019. n.d.","journal-title":"J Clin Oncol"},{"issue":"7","key":"2487_CR60","doi-asserted-by":"publisher","first-page":"S1428","DOI":"10.1016\/annonc\/annonc1103","volume":"33","author":"LL Siu","year":"2022","unstructured":"Siu LL, Even C, Le Tourneau C, et al. Phase II study of neoadjuvant pembrolizumab plus cetuximab in resectable hypopharyngeal squamous cell carcinoma (EACH trial): Biomarker correlates of response. Annals of Oncology. 2022;33(7):S1428. https:\/\/doi.org\/10.1016\/annonc\/annonc1103. n.d.","journal-title":"Annals of Oncology."},{"key":"2487_CR61","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1213222","volume":"14","author":"Y Shi","year":"2023","unstructured":"Shi Y, Ma X, He D, Dong B, Qiao T. Neoadjuvant SBRT combined with immunotherapy in NSCLC: from mechanisms to therapy. Front Immunol. 2023;14:1213222. https:\/\/doi.org\/10.3389\/fimmu.2023.1213222.","journal-title":"Front Immunol"},{"key":"2487_CR62","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.956984","volume":"13","author":"H Zhang","year":"2022","unstructured":"Zhang H, Ye L, Yu X, Jin K, Wu W. Neoadjuvant therapy alters the immune microenvironment in pancreatic cancer. Front Immunol. 2022;13:956984. https:\/\/doi.org\/10.3389\/fimmu.2022.956984.","journal-title":"Front Immunol"},{"key":"2487_CR63","doi-asserted-by":"publisher","DOI":"10.1172\/JCI137001","volume":"131","author":"D Moreira","year":"2021","unstructured":"Moreira D, Sampath S, Won H, White SV, Su Y-L, Alcantara M, et al. Myeloid cell-targeted STAT3 inhibition sensitizes head and neck cancers to radiotherapy and T cell-mediated immunity. J Clin Invest. 2021;131:e137001. https:\/\/doi.org\/10.1172\/JCI137001.","journal-title":"J Clin Invest"},{"key":"2487_CR64","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2016-000122","volume":"1","author":"P Economopoulou","year":"2016","unstructured":"Economopoulou P, Kotsantis I, Psyrri A. The promise of immunotherapy in head and neck squamous cell carcinoma: combinatorial immunotherapy approaches. ESMO Open. 2016;1:e000122. https:\/\/doi.org\/10.1136\/esmoopen-2016-000122.","journal-title":"ESMO Open"},{"key":"2487_CR65","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1108213","volume":"14","author":"H Qin","year":"2023","unstructured":"Qin H, Liu F, Zhang Y, Liang Y, Mi Y, Yu F, et al. Comparison of neoadjuvant immunotherapy versus routine neoadjuvant therapy for patients with locally advanced esophageal cancer: a systematic review and meta-analysis. Front Immunol. 2023;14:1108213. https:\/\/doi.org\/10.3389\/fimmu.2023.1108213.","journal-title":"Front Immunol"},{"key":"2487_CR66","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1117448","volume":"14","author":"Y Liu","year":"2023","unstructured":"Liu Y, Bao Y, Yang X, Sun S, Yuan M, Ma Z, et al. Efficacy and safety of neoadjuvant immunotherapy combined with chemoradiotherapy or chemotherapy in esophageal cancer: a systematic review and meta-analysis. Front Immunol. 2023;14:1117448. https:\/\/doi.org\/10.3389\/fimmu.2023.1117448.","journal-title":"Front Immunol"},{"issue":"16suppl","key":"2487_CR67","doi-asserted-by":"publisher","first-page":"6007","DOI":"10.1200\/JCO.2022.40.16_suppl.6007","volume":"40","author":"T Wise-Draper","year":"2022","unstructured":"Wise-Draper T, Gibson MK, Ferrarotto R, et al. Phase Ib\/II neoadjuvant pembrolizumab with chemotherapy in local-regionally advanced head and neck squamous cell carcinoma: immunotherapy assessment of surgical specimens (IMPASSE). J Clin Oncol. 2022;40(16suppl):6007. https:\/\/doi.org\/10.1200\/JCO.2022.40.16_suppl.6007.","journal-title":"J Clin Oncol"},{"key":"2487_CR68","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1016\/j.it.2016.04.010","volume":"37","author":"PE Hughes","year":"2016","unstructured":"Hughes PE, Caenepeel S, Wu LC. Targeted therapy and checkpoint immunotherapy combinations for the treatment of cancer. Trends Immunol. 2016;37:462\u201376. https:\/\/doi.org\/10.1016\/j.it.2016.04.010.","journal-title":"Trends Immunol"},{"key":"2487_CR69","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1038\/nrclinonc.2014.221","volume":"12","author":"A Errico","year":"2014","unstructured":"Errico A. PD-1-PD-L1 axis: efficient checkpoint blockade against cancer. Nat Rev Clin Oncol. 2014;12:63\u201363. https:\/\/doi.org\/10.1038\/nrclinonc.2014.221.","journal-title":"Nat Rev Clin Oncol"},{"key":"2487_CR70","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1056\/NEJMoa1602252","volume":"375","author":"RL Ferris","year":"2016","unstructured":"Ferris RL, Blumenschein G, Fayette J, Guigay J, Colevas AD, Licitra L, et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med. 2016;375:1856\u201367. https:\/\/doi.org\/10.1056\/NEJMoa1602252.","journal-title":"N Engl J Med"},{"key":"2487_CR71","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/s41571-024-00969-w","volume":"22","author":"M Zhao","year":"2024","unstructured":"Zhao M, Schoenfeld JD, Egloff AM, Hanna GJ, Haddad RI, Adkins DR, et al. T cell dynamics with neoadjuvant immunotherapy in head and neck cancer. Nat Rev Clin Oncol. 2024;22:83\u201394. https:\/\/doi.org\/10.1038\/s41571-024-00969-w.","journal-title":"Nat Rev Clin Oncol"},{"key":"2487_CR72","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1056\/NEJMoa2211437","volume":"388","author":"SP Patel","year":"2023","unstructured":"Patel SP, Othus M, Chen Y, Wright GP, Yost KJ, Hyngstrom JR, et al. Neoadjuvant-adjuvant or adjuvant-only pembrolizumab in advanced melanoma. N Engl J Med. 2023;388:813\u201323. https:\/\/doi.org\/10.1056\/NEJMoa2211437.","journal-title":"N Engl J Med"},{"key":"2487_CR73","doi-asserted-by":"publisher","unstructured":"Uppaluri R, Haddad RI, Tao Y, Le Tourneau C, Lee NY, Westra W, et al. Neoadjuvant and adjuvant pembrolizumab in locally advanced head and neck cancer. N Engl J Med. 2025;393:37\u201350. https:\/\/doi.org\/10.1056\/NEJMoa2415434.","DOI":"10.1056\/NEJMoa2415434"},{"key":"2487_CR74","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-024-01838-9","volume":"9","author":"F He","year":"2024","unstructured":"He F, Wu Z, Liu C, Zhu Y, Zhou Y, Tian E, et al. Targeting BCL9\/BCL9L enhances antigen presentation by promoting conventional type 1 dendritic cell (cDC1) activation and tumor infiltration. Signal Transduct Target Ther. 2024;9:139. https:\/\/doi.org\/10.1038\/s41392-024-01838-9.","journal-title":"Signal Transduct Target Ther"},{"key":"2487_CR75","doi-asserted-by":"publisher","DOI":"10.1126\/science.adn9083","volume":"386","author":"E Ascic","year":"2024","unstructured":"Ascic E, \u00c5kerstr\u00f6m F, Sreekumar Nair M, Rosa A, Kurochkin I, Zimmermannova O, et al. In vivo dendritic cell reprogramming for cancer immunotherapy. Science. 2024;386:eadn9083. https:\/\/doi.org\/10.1126\/science.adn9083.","journal-title":"Science"},{"key":"2487_CR76","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1158\/2326-6066.CIR-18-0061","volume":"7","author":"HS Ma","year":"2019","unstructured":"Ma HS, Poudel B, Torres ER, Sidhom J-W, Robinson TM, Christmas B, et al. A CD40 agonist and PD-1 antagonist antibody reprogram the microenvironment of nonimmunogenic tumors to allow T-cell-mediated anticancer activity. Cancer Immunol Res. 2019;7:428\u201342. https:\/\/doi.org\/10.1158\/2326-6066.CIR-18-0061.","journal-title":"Cancer Immunol Res"},{"key":"2487_CR77","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13050968","volume":"13","author":"LA Horn","year":"2021","unstructured":"Horn LA, Fousek K, Hamilton DH, Hodge JW, Zebala JA, Maeda DY, et al. Vaccine increases the diversity and activation of intratumoral T cells in the context of combination immunotherapy. Cancers (Basel). 2021;13:968. https:\/\/doi.org\/10.3390\/cancers13050968.","journal-title":"Cancers (Basel)"},{"key":"2487_CR78","doi-asserted-by":"publisher","first-page":"1620","DOI":"10.4161\/onci.21514","volume":"1","author":"B H\u00f6chst","year":"2012","unstructured":"H\u00f6chst B, Diehl L. Antigen shedding into the circulation contributes to tumor immune escape. Oncoimmunology. 2012;1:1620\u20132. https:\/\/doi.org\/10.4161\/onci.21514.","journal-title":"Oncoimmunology"},{"key":"2487_CR79","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.coi.2012.03.001","volume":"24","author":"L Meyaard","year":"2012","unstructured":"Meyaard L, Smyth MJ. Liberating tumor immunity. Curr Opin Immunol. 2012;24:204\u20136. https:\/\/doi.org\/10.1016\/j.coi.2012.03.001.","journal-title":"Curr Opin Immunol"},{"key":"2487_CR80","doi-asserted-by":"publisher","first-page":"1","DOI":"10.21147\/j.issn.1000-9604.2022.01.01","volume":"34","author":"DT X","year":"2022","unstructured":"X DT. Inducing Immunogenic cell death in immuno-oncological therapies. Chin J Cancer Res. 2022;34:1\u201310. https:\/\/doi.org\/10.21147\/j.issn.1000-9604.2022.01.01.","journal-title":"Chin J Cancer Res"},{"key":"2487_CR81","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1038\/nrc3380","volume":"12","author":"DV Krysko","year":"2012","unstructured":"Krysko DV, Garg AD, Kaczmarek A, Krysko O, Agostinis P, Vandenabeele P. Immunogenic cell death and DAMPs in cancer therapy. Nat Rev Cancer. 2012;12:860\u201375. https:\/\/doi.org\/10.1038\/nrc3380.","journal-title":"Nat Rev Cancer"},{"key":"2487_CR82","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1016\/j.immuni.2014.10.017","volume":"41","author":"S-R Woo","year":"2014","unstructured":"Woo S-R, Fuertes MB, Corrales L, Spranger S, Furdyna MJ, Leung MYK, et al. STING-dependent cytosolic DNA sensing mediates innate immune recognition of Immunogenic tumors. Immunity. 2014;41:830\u201342. https:\/\/doi.org\/10.1016\/j.immuni.2014.10.017.","journal-title":"Immunity"},{"key":"2487_CR83","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1016\/j.immuni.2014.10.019","volume":"41","author":"L Deng","year":"2014","unstructured":"Deng L, Liang H, Xu M, Yang X, Burnette B, Arina A, et al. STING-dependent cytosolic DNA sensing promotes radiation-induced type I interferon-dependent antitumor immunity in immunogenic tumors. Immunity. 2014;41:843\u201352. https:\/\/doi.org\/10.1016\/j.immuni.2014.10.019.","journal-title":"Immunity"},{"key":"2487_CR84","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1016\/j.immuni.2016.04.010","volume":"44","author":"SSW Ho","year":"2016","unstructured":"Ho SSW, Zhang WYL, Tan NYJ, Khatoo M, Suter MA, Tripathi S, et al. The DNA Structure-Specific endonuclease MUS81 mediates DNA sensor STING-Dependent host rejection of prostate cancer cells. Immunity. 2016;44:1177\u201389. https:\/\/doi.org\/10.1016\/j.immuni.2016.04.010.","journal-title":"Immunity"},{"key":"2487_CR85","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1038\/s41586-020-03151-1","volume":"591","author":"CR Donnelly","year":"2021","unstructured":"Donnelly CR, Jiang C, Andriessen AS, Wang K, Wang Z, Ding H, et al. STING controls nociception via type i interferon signalling in sensory neurons. Nature. 2021;591:275\u201380. https:\/\/doi.org\/10.1038\/s41586-020-03151-1.","journal-title":"Nature"},{"key":"2487_CR86","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/j.immuni.2016.02.004","volume":"44","author":"EC Carroll","year":"2016","unstructured":"Carroll EC, Jin L, Mori A, Mu\u00f1oz-Wolf N, Oleszycka E, Moran HBT, et al. The vaccine adjuvant chitosan promotes cellular immunity via DNA sensor cGAS-STING-dependent induction of type I interferons. Immunity. 2016;44:597\u2013608. https:\/\/doi.org\/10.1016\/j.immuni.2016.02.004.","journal-title":"Immunity"},{"key":"2487_CR87","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1200\/JCO.2017.75.3384","volume":"36","author":"H Rizvi","year":"2018","unstructured":"Rizvi H, Sanchez-Vega F, La K, Chatila W, Jonsson P, Halpenny D, et al. Molecular determinants of response to anti-programmed cell death (PD)-1 and anti-programmed death-ligand 1 (PD-L1) blockade in patients with non-small-cell lung cancer profiled with targeted next-generation sequencing. J Clin Oncol. 2018;36:633\u201341. https:\/\/doi.org\/10.1200\/JCO.2017.75.3384.","journal-title":"J Clin Oncol"},{"key":"2487_CR88","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/s41588-018-0312-8","volume":"51","author":"RM Samstein","year":"2019","unstructured":"Samstein RM, Lee C-H, Shoushtari AN, Hellmann MD, Shen R, Janjigian YY, et al. Tumor mutational load predicts survival after immunotherapy across multiple cancer types. Nat Genet. 2019;51:202\u20136. https:\/\/doi.org\/10.1038\/s41588-018-0312-8.","journal-title":"Nat Genet"},{"key":"2487_CR89","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2024.101095","volume":"76","author":"H Cao","year":"2024","unstructured":"Cao H, Lan T, Kuang S, Wang L, Li J, Li Q, et al. FAT1 as a tumor mutation burden specific gene affects the immunotherapy effect in head and neck squamous cell cancer. Drug Resist Updat. 2024;76:101095. https:\/\/doi.org\/10.1016\/j.drup.2024.101095.","journal-title":"Drug Resist Updat"},{"key":"2487_CR90","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-21383-1","volume":"12","author":"R Duhen","year":"2021","unstructured":"Duhen R, Ballesteros-Merino C, Frye AK, Tran E, Rajamanickam V, Chang S-C, et al. Neoadjuvant anti-OX40 (MEDI6469) therapy in patients with head and neck squamous cell carcinoma activates and expands antigen-specific tumor-infiltrating T cells. Nat Commun. 2021;12:1047. https:\/\/doi.org\/10.1038\/s41467-021-21383-1.","journal-title":"Nat Commun"},{"key":"2487_CR91","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2018.1494112","volume":"7","author":"BA Kansy","year":"2018","unstructured":"Kansy BA, Shayan G, Jie H-B, Gibson SP, Lei YL, Brandau S, et al. T cell receptor richness in peripheral blood increases after cetuximab therapy and correlates with therapeutic response. Oncoimmunology. 2018;7:e1494112. https:\/\/doi.org\/10.1080\/2162402X.2018.1494112.","journal-title":"Oncoimmunology"},{"key":"2487_CR92","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-24-02138","author":"S Bhatia","year":"2025","unstructured":"Bhatia S, Topalian SL, Sharfman W, Meyer T, Steven N, Lao CD, et al. Nivolumab with or without ipilimumab in patients with recurrent or metastatic Merkel cell carcinoma: a nonrandomized, open-label, international, multicenter phase I\/II study. J Clin Oncol. 2025. https:\/\/doi.org\/10.1200\/JCO-24-02138.","journal-title":"J Clin Oncol"},{"key":"2487_CR93","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-18570-x","volume":"11","author":"Q Peng","year":"2020","unstructured":"Peng Q, Qiu X, Zhang Z, Zhang S, Zhang Y, Liang Y, et al. PD-L1 on dendritic cells attenuates T cell activation and regulates response to immune checkpoint blockade. Nat Commun. 2020;11:4835. https:\/\/doi.org\/10.1038\/s41467-020-18570-x.","journal-title":"Nat Commun"},{"key":"2487_CR94","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aav7431","volume":"12","author":"M Mayoux","year":"2020","unstructured":"Mayoux M, Roller A, Pulko V, Sammicheli S, Chen S, Sum E, et al. Dendritic cells dictate responses to PD-L1 blockade cancer immunotherapy. Sci Transl Med. 2020;12:eaav7431. https:\/\/doi.org\/10.1126\/scitranslmed.aav7431.","journal-title":"Sci Transl Med"},{"key":"2487_CR95","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/j.ccell.2016.06.003","volume":"30","author":"EW Roberts","year":"2016","unstructured":"Roberts EW, Broz ML, Binnewies M, Headley MB, Nelson AE, Wolf DM, et al. Critical role for CD103(+)\/CD141(+) dendritic cells bearing CCR7 for tumor antigen trafficking and priming of T cell immunity in melanoma. Cancer Cell. 2016;30:324\u201336. https:\/\/doi.org\/10.1016\/j.ccell.2016.06.003.","journal-title":"Cancer Cell"},{"key":"2487_CR96","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1126\/science.aav7062","volume":"364","author":"D Sugiura","year":"2019","unstructured":"Sugiura D, Maruhashi T, Okazaki I-M, Shimizu K, Maeda TK, Takemoto T, et al. Restriction of PD-1 function by cis-PD-L1\/CD80 interactions is required for optimal T cell responses. Science. 2019;364:558\u201366. https:\/\/doi.org\/10.1126\/science.aav7062.","journal-title":"Science"},{"key":"2487_CR97","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1038\/s41586-020-2134-y","volume":"580","author":"B Maier","year":"2020","unstructured":"Maier B, Leader AM, Chen ST, Tung N, Chang C, LeBerichel J, et al. A conserved dendritic-cell regulatory program limits antitumour immunity. Nature. 2020;580:257\u201362. https:\/\/doi.org\/10.1038\/s41586-020-2134-y.","journal-title":"Nature"},{"key":"2487_CR98","doi-asserted-by":"publisher","unstructured":"He J, Shen J, Luo W, et al. Research progress on application of single-cell TCR\/BCR sequencing technology to the tumor immune microenvironment, autoimmune diseases, and infectious diseases. Front Immunol. 2022;13:969808. https:\/\/doi.org\/10.3389\/fimmu.2022.969808.","DOI":"10.3389\/fimmu.2022.969808"},{"key":"2487_CR99","doi-asserted-by":"publisher","unstructured":"Li S, Yao JC, Li JT, Schmidt AP, Link DC. TLR7\/8 agonist treatment induces an increase in bone marrow resident dendritic cells and hematopoietic progenitor expansion and mobilization. Exp Hematol. 2021;96:35\u201343.e7. https:\/\/doi.org\/10.1016\/j.exphem.2021.02.001.","DOI":"10.1016\/j.exphem.2021.02.001"},{"key":"2487_CR100","doi-asserted-by":"publisher","unstructured":"Mullins SR, Vasilakos JP, Deschler K, et al. Intratumoral immunotherapy with TLR7\/8 agonist MEDI9197 modulates the tumor microenvironment leading to enhanced activity when combined with other immunotherapies. J Immunother Cancer. 2019;7(1):244. https:\/\/doi.org\/10.1186\/s40425-019-0724-8.","DOI":"10.1186\/s40425-019-0724-8"},{"key":"2487_CR101","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1111\/bph.12530","volume":"171","author":"S Das","year":"2014","unstructured":"Das S, Rani M, Rabidas V, Pandey K, Sahoo GC, Das P. TLR9 and MyD88 are crucial for the maturation and activation of dendritic cells by paromomycin-miltefosine combination therapy in visceral leishmaniasis. Br J Pharmacol. 2014;171:1260\u201374. https:\/\/doi.org\/10.1111\/bph.12530.","journal-title":"Br J Pharmacol"},{"key":"2487_CR102","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.1021\/acs.molpharmaceut.0c00271","volume":"17","author":"H Kim","year":"2020","unstructured":"Kim H, Khanna V, Kucaba TA, Zhang W, Sehgal D, Ferguson DM, et al. TLR7\/8 agonist-loaded nanoparticles augment NK cell-mediated antibody-based cancer immunotherapy. Mol Pharm. 2020;17:2109\u201324. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.0c00271.","journal-title":"Mol Pharm"},{"key":"2487_CR103","doi-asserted-by":"publisher","DOI":"10.4161\/onci.24660","volume":"2","author":"S Koido","year":"2013","unstructured":"Koido S, Homma S, Okamoto M, Namiki Y, Takakura K, Uchiyama K, et al. The combination of TLR2 and TLR4 agonists promotes the immunogenicity of dendritic cell\/cancer cell fusions. Oncoimmunology. 2013;2:e24660. https:\/\/doi.org\/10.4161\/onci.24660.","journal-title":"Oncoimmunology"},{"key":"2487_CR104","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0007334","volume":"4","author":"GW Stone","year":"2009","unstructured":"Stone GW, Barzee S, Snarsky V, Santucci C, Tran B, Langer R, et al. Nanoparticle-delivered multimeric soluble CD40L DNA combined with toll-like receptor agonists as a treatment for melanoma. PLoS ONE. 2009;4:e7334. https:\/\/doi.org\/10.1371\/journal.pone.0007334.","journal-title":"PLoS ONE"},{"key":"2487_CR105","doi-asserted-by":"publisher","first-page":"3377","DOI":"10.1172\/JCI80012","volume":"125","author":"E Buchbinder","year":"2015","unstructured":"Buchbinder E, Hodi FS. Cytotoxic t lymphocyte antigen-4 and immune checkpoint blockade. J Clin Invest. 2015;125:3377\u201383. https:\/\/doi.org\/10.1172\/JCI80012.","journal-title":"J Clin Invest"},{"key":"2487_CR106","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1016\/j.ccell.2020.09.001","volume":"38","author":"F Dammeijer","year":"2020","unstructured":"Dammeijer F, van Gulijk M, Mulder EE, Lukkes M, Klaase L, van den Bosch T, et al. The PD-1\/PD-L1-Checkpoint restrains T cell immunity in Tumor-Draining lymph nodes. Cancer Cell. 2020;38:685\u2013e7008. https:\/\/doi.org\/10.1016\/j.ccell.2020.09.001.","journal-title":"Cancer Cell"},{"key":"2487_CR107","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1084\/jem.20130579","volume":"210","author":"TR Simpson","year":"2013","unstructured":"Simpson TR, Li F, Montalvo-Ortiz W, Sepulveda MA, Bergerhoff K, Arce F, et al. Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma. J Exp Med. 2013;210:1695\u2013710. https:\/\/doi.org\/10.1084\/jem.20130579.","journal-title":"J Exp Med"},{"key":"2487_CR108","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1158\/0008-5472.CAN-13-2752","volume":"74","author":"J Duraiswamy","year":"2014","unstructured":"Duraiswamy J, Freeman GJ, Coukos G. Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors\u2013response. Cancer Res. 2014;74:633\u20134. https:\/\/doi.org\/10.1158\/0008-5472.CAN-13-2752.","journal-title":"Cancer Res"},{"key":"2487_CR109","doi-asserted-by":"publisher","unstructured":"Li N, Yuan J, Tian W, Meng L, Liu Y. T-cell receptor repertoire analysis for the diagnosis and treatment of solid tumor: a methodology and clinical applications. Cancer Commun (Lond). 2020;40(10):473\u201383. https:\/\/doi.org\/10.1002\/cac2.12074.","DOI":"10.1002\/cac2.12074"},{"key":"2487_CR110","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.00385","volume":"10","author":"EA Zhigalova","year":"2020","unstructured":"Zhigalova EA, Izosimova AI, Yuzhakova DV, Volchkova LN, Shagina IA, Turchaninova MA, et al. RNA-seq-based TCR profiling reveals persistently increased intratumoral clonality in responders to anti-PD-1 therapy. Front Oncol. 2020;10:385. https:\/\/doi.org\/10.3389\/fonc.2020.00385.","journal-title":"Front Oncol"},{"key":"2487_CR111","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1158\/1078-0432.CCR-22-2355","volume":"29","author":"H Ge","year":"2022","unstructured":"Ge H, Ferris RL, Wang JH. Cetuximab responses in patients with HNSCC correlate to clonal expansion feature of peripheral and Tumor-Infiltrating T cells with top T-Cell receptor clonotypes. Clin Cancer Res. 2022;29:647\u201358. https:\/\/doi.org\/10.1158\/1078-0432.CCR-22-2355.","journal-title":"Clin Cancer Res"},{"key":"2487_CR112","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-004512","volume":"10","author":"X Wang","year":"2022","unstructured":"Wang X, Muzaffar J, Kirtane K, Song F, Johnson M, Schell MJ, et al. T cell repertoire in peripheral blood as a potential biomarker for predicting response to concurrent cetuximab and nivolumab in head and neck squamous cell carcinoma. J Immunother Cancer. 2022;10:e004512. https:\/\/doi.org\/10.1136\/jitc-2022-004512.","journal-title":"J Immunother Cancer"},{"key":"2487_CR113","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20200921","volume":"218","author":"LE Lucca","year":"2021","unstructured":"Lucca LE, Axisa P-P, Lu B, Harnett B, Jessel S, Zhang L, et al. Circulating clonally expanded T cells reflect functions of tumor-infiltrating T cells. J Exp Med. 2021;218:e20200921. https:\/\/doi.org\/10.1084\/jem.20200921.","journal-title":"J Exp Med"},{"key":"2487_CR114","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.coi.2021.07.006","volume":"74","author":"K Joshi","year":"2022","unstructured":"Joshi K, Milighetti M, Chain BM. Application of T cell receptor (TCR) repertoire analysis for the advancement of cancer immunotherapy. Curr Opin Immunol. 2022;74:1\u20138. https:\/\/doi.org\/10.1016\/j.coi.2021.07.006.","journal-title":"Curr Opin Immunol"},{"key":"2487_CR115","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.1038\/s41591-020-1006-1","volume":"26","author":"FZ Cader","year":"2020","unstructured":"Cader FZ, Hu X, Goh WL, Wienand K, Ouyang J, Mandato E, et al. A peripheral immune signature of responsiveness to PD-1 blockade in patients with classical hodgkin lymphoma. Nat Med. 2020;26:1468\u201379. https:\/\/doi.org\/10.1038\/s41591-020-1006-1.","journal-title":"Nat Med"},{"key":"2487_CR116","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1038\/s41591-019-0734-6","volume":"26","author":"BP Fairfax","year":"2020","unstructured":"Fairfax BP, Taylor CA, Watson RA, Nassiri I, Danielli S, Fang H, et al. Peripheral CD8\u2009+\u2009T cell characteristics associated with durable responses to immune checkpoint blockade in patients with metastatic melanoma. Nat Med. 2020;26:193\u20139. https:\/\/doi.org\/10.1038\/s41591-019-0734-6.","journal-title":"Nat Med"},{"key":"2487_CR117","doi-asserted-by":"publisher","first-page":"2825","DOI":"10.1200\/JCO.19.00739","volume":"37","author":"RW Naumann","year":"2019","unstructured":"Naumann RW, Hollebecque A, Meyer T, Devlin M-J, Oaknin A, Kerger J, et al. Safety and efficacy of nivolumab monotherapy in recurrent or metastatic cervical, vaginal, or vulvar carcinoma: results from the phase I\/II checkmate 358 trial. J Clin Oncol. 2019;37:2825\u201334. https:\/\/doi.org\/10.1200\/JCO.19.00739.","journal-title":"J Clin Oncol"},{"key":"2487_CR118","doi-asserted-by":"publisher","first-page":"xii18","DOI":"10.1093\/annonc\/mdx238","volume":"28","author":"E Lanitis","year":"2017","unstructured":"Lanitis E, Dangaj D, Irving M, Coukos G. Mechanisms regulating T-cell infiltration and activity in solid tumors. Ann Oncol. 2017;28:xii18\u201332. https:\/\/doi.org\/10.1093\/annonc\/mdx238.","journal-title":"Ann Oncol"},{"key":"2487_CR119","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1146\/annurev-immunol-041015-055318","volume":"37","author":"LM McLane","year":"2019","unstructured":"McLane LM, Abdel-Hakeem MS, Wherry EJ. CD8 T cell exhaustion during chronic viral infection and cancer. Annu Rev Immunol. 2019;37:457\u201395. https:\/\/doi.org\/10.1146\/annurev-immunol-041015-055318.","journal-title":"Annu Rev Immunol"},{"key":"2487_CR120","doi-asserted-by":"publisher","unstructured":"Zhao R, Song Y, Wang Y, et al. PD-1\/PD-L1 blockade rescue exhausted CD8+ T cells in gastrointestinal stromal tumours via the PI3K\/Akt\/mTOR signalling pathway. Cell Prolif. 2019;52(3):e12571. https:\/\/doi.org\/10.1111\/cpr.12571.","DOI":"10.1111\/cpr.12571"},{"key":"2487_CR121","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1158\/0008-5472.CAN-14-3362","volume":"76","author":"KJ Lastwika","year":"2016","unstructured":"Lastwika KJ, Wilson W, Li QK, Norris J, Xu H, Ghazarian SR, et al. Control of PD-L1 expression by oncogenic activation of the AKT-mTOR pathway in non-small cell lung cancer. Cancer Res. 2016;76:227\u201338. https:\/\/doi.org\/10.1158\/0008-5472.CAN-14-3362.","journal-title":"Cancer Res"},{"key":"2487_CR122","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms7692","volume":"6","author":"N Patsoukis","year":"2015","unstructured":"Patsoukis N, Bardhan K, Chatterjee P, Sari D, Liu B, Bell LN, et al. PD-1 alters T-cell metabolic reprogramming by inhibiting glycolysis and promoting lipolysis and fatty acid oxidation. Nat Commun. 2015;6:6692. https:\/\/doi.org\/10.1038\/ncomms7692.","journal-title":"Nat Commun"},{"key":"2487_CR123","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1158\/0008-5472.CAN-16-0274","volume":"77","author":"C Granier","year":"2017","unstructured":"Granier C, Dariane C, Combe P, Verkarre V, Urien S, Badoual C, et al. Tim-3 expression on tumor-infiltrating PD-1\u2009+\u2009CD8\u2009+\u2009T cells correlates with poor clinical outcome in renal cell carcinoma. Cancer Res. 2017;77:1075\u201382. https:\/\/doi.org\/10.1158\/0008-5472.CAN-16-0274.","journal-title":"Cancer Res"},{"key":"2487_CR124","doi-asserted-by":"publisher","unstructured":"Takano S, Saito H, Ikeguchi M. An increased number of PD-1+ and Tim-3+ CD8+ T cells is involved in immune evasion in gastric cancer. Surg Today. 2016;46(11):1341\u201347. https:\/\/doi.org\/10.1007\/s00595-016-1305-9.","DOI":"10.1007\/s00595-016-1305-9"},{"key":"2487_CR125","doi-asserted-by":"publisher","first-page":"4501","DOI":"10.1182\/blood-2010-10-310425","volume":"117","author":"Q Zhou","year":"2011","unstructured":"Zhou Q, Munger ME, Veenstra RG, Weigel BJ, Hirashima M, Munn DH, et al. Coexpression of Tim-3 and PD-1 identifies a CD8\u2009+\u2009T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia. Blood. 2011;117:4501\u201310. https:\/\/doi.org\/10.1182\/blood-2010-10-310425.","journal-title":"Blood"},{"key":"2487_CR126","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1093\/intimm\/dxaa010","volume":"32","author":"M Sawada","year":"2020","unstructured":"Sawada M, Goto K, Morimoto-Okazawa A, Haruna M, Yamamoto K, Yamamoto Y, et al. PD-1\u2009+\u2009Tim3\u2009+\u2009tumor-infiltrating CD8 T cells sustain the potential for IFN-\u03b3 production, but lose cytotoxic activity in ovarian cancer. Int Immunol. 2020;32:397\u2013405. https:\/\/doi.org\/10.1093\/intimm\/dxaa010.","journal-title":"Int Immunol"},{"key":"2487_CR127","doi-asserted-by":"publisher","first-page":"2121","DOI":"10.1182\/blood.2024024590","volume":"144","author":"M John","year":"2024","unstructured":"John M, Helal M, Duell J, Mattavelli G, Stanojkovska E, Afrin N, et al. Spatial transcriptomics reveals profound subclonal heterogeneity and T-cell dysfunction in extramedullary myeloma. Blood. 2024;144:2121\u201335. https:\/\/doi.org\/10.1182\/blood.2024024590.","journal-title":"Blood"},{"key":"2487_CR128","doi-asserted-by":"publisher","unstructured":"Peng W, Liu C, Xu C, et al. PD-1 blockade enhances T-cell migration to tumors by elevating IFN-\u03b3 inducible chemokines. Cancer Res. 2012;72(20):5209\u201318. https:\/\/doi.org\/10.1158\/0008-5472.CAN-12-1187.","DOI":"10.1158\/0008-5472.CAN-12-1187"},{"key":"2487_CR129","doi-asserted-by":"publisher","first-page":"e0212513","DOI":"10.1371\/journal.pone.0212513","volume":"14","author":"YK K","year":"2019","unstructured":"K YK, A Y-K TTK. Lenvatinib plus anti-PD-1 antibody combination treatment activates CD8\u2009+\u2009T cells through reduction of tumor-associated macrophage and activation of the interferon pathway. PLoS ONE. 2019;14:e0212513. https:\/\/doi.org\/10.1371\/journal.pone.0212513.","journal-title":"PLoS ONE"},{"key":"2487_CR130","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1016\/j.ccell.2021.03.007","volume":"39","author":"C Krishna","year":"2021","unstructured":"Krishna C, DiNatale RG, Kuo F, Srivastava RM, Vuong L, Chowell D, et al. Single-cell sequencing links multiregional immune landscapes and tissue-resident T cells in CcRCC to tumor topology and therapy efficacy. Cancer Cell. 2021;39:662\u2013e6776. https:\/\/doi.org\/10.1016\/j.ccell.2021.03.007.","journal-title":"Cancer Cell"},{"key":"2487_CR131","doi-asserted-by":"publisher","unstructured":"Zhang H, AbdulJabbar K, Moore DA, et al. Spatial positioning of immune hotspots reflects the interplay between B and T cells in lung squamous cell carcinoma. Cancer Res. 2023;83(9):1410\u201325. https:\/\/doi.org\/10.1158\/0008-5472.CAN-22-2589.","DOI":"10.1158\/0008-5472.CAN-22-2589"},{"key":"2487_CR132","doi-asserted-by":"publisher","first-page":"2520","DOI":"10.1084\/jem.20180684","volume":"215","author":"J Brummelman","year":"2018","unstructured":"Brummelman J, Mazza EMC, Alvisi G, Colombo FS, Grilli A, Mikulak J, et al. High-dimensional single cell analysis identifies stem-like cytotoxic CD8\u2009+\u2009T cells infiltrating human tumors. J Exp Med. 2018;215:2520\u201335. https:\/\/doi.org\/10.1084\/jem.20180684.","journal-title":"J Exp Med"},{"key":"2487_CR133","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.1038\/s41590-022-01338-4","volume":"23","author":"JR Giles","year":"2022","unstructured":"Giles JR, Ngiow SF, Manne S, Baxter AE, Khan O, Wang P, et al. Shared and distinct biological circuits in effector, memory and exhausted CD8\u2009+\u2009T cells revealed by temporal single-cell transcriptomics and epigenetics. Nat Immunol. 2022;23:1600\u201313. https:\/\/doi.org\/10.1038\/s41590-022-01338-4.","journal-title":"Nat Immunol"},{"key":"2487_CR134","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1038\/s41590-019-0312-6","volume":"20","author":"M Bc","year":"2019","unstructured":"Bc M, Dr S, R AA, Yv KB, Mw V. Subsets of exhausted CD8\u2009+\u2009T cells differentially mediate tumor control and respond to checkpoint Blockade. Nat Immunol. 2019;20:326\u201336. https:\/\/doi.org\/10.1038\/s41590-019-0312-6.","journal-title":"Nat Immunol"},{"key":"2487_CR135","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1016\/j.immuni.2020.04.014","volume":"52","author":"J-C Beltra","year":"2020","unstructured":"Beltra J-C, Manne S, Abdel-Hakeem MS, Kurachi M, Giles JR, Chen Z, et al. Developmental relationships of four exhausted CD8\u2009+\u2009T cell subsets reveals underlying transcriptional and epigenetic landscape control mechanisms. Immunity. 2020;52:825\u2013e8418. https:\/\/doi.org\/10.1016\/j.immuni.2020.04.014.","journal-title":"Immunity"},{"key":"2487_CR136","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2019-000452","volume":"8","author":"R Hewavisenti","year":"2020","unstructured":"Hewavisenti R, Ferguson A, Wang K, Jones D, Gebhardt T, Edwards J, et al. CD103\u2009+\u2009tumor-resident CD8\u2009+\u2009T cell numbers underlie improved patient survival in oropharyngeal squamous cell carcinoma. J Immunother Cancer. 2020;8:e000452. https:\/\/doi.org\/10.1136\/jitc-2019-000452.","journal-title":"J Immunother Cancer"},{"key":"2487_CR137","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1158\/1078-0432.CCR-23-0445","volume":"30","author":"A von Witzleben","year":"2023","unstructured":"von Witzleben A, Ellis M, Thomas GJ, Hoffmann TK, Jackson R, Laban S, et al. Tumor-infiltrating CD103\u2009+\u2009tissue-resident memory T cells and CD103-CD8\u2009+\u2009T cells in HNSCC are linked to outcome in primary but not metastatic disease. Clin Cancer Res. 2023;30:224\u201334. https:\/\/doi.org\/10.1158\/1078-0432.CCR-23-0445.","journal-title":"Clin Cancer Res"},{"key":"2487_CR138","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1016\/j.immuni.2021.06.013","volume":"54","author":"Y Cheng","year":"2021","unstructured":"Cheng Y, Gunasegaran B, Singh HD, Dutertre C-A, Loh CY, Lim JQ, et al. Non-terminally exhausted tumor-resident memory HBV-specific T cell responses correlate with relapse-free survival in hepatocellular carcinoma. Immunity. 2021;54:1825\u2013e18407. https:\/\/doi.org\/10.1016\/j.immuni.2021.06.013.","journal-title":"Immunity"},{"key":"2487_CR139","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-000778","volume":"8","author":"EM Garrido-Martin","year":"2020","unstructured":"Garrido-Martin EM, Mellows TWP, Clarke J, Ganesan A-P, Wood O, Cazaly A, et al. M1hot tumor-associated macrophages boost tissue-resident memory T cells infiltration and survival in human lung cancer. J Immunother Cancer. 2020;8:e000778. https:\/\/doi.org\/10.1136\/jitc-2020-000778.","journal-title":"J Immunother Cancer"},{"key":"2487_CR140","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001955","volume":"9","author":"MW Knitz","year":"2021","unstructured":"Knitz MW, Bickett TE, Darragh LB, Oweida AJ, Bhatia S, Van Court B, et al. Targeting resistance to radiation-immunotherapy in cold HNSCCs by modulating the Treg-dendritic cell axis. J Immunother Cancer. 2021;9:e001955. https:\/\/doi.org\/10.1136\/jitc-2020-001955.","journal-title":"J Immunother Cancer"},{"key":"2487_CR141","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/j.trecan.2017.06.005","volume":"3","author":"H Wang","year":"2017","unstructured":"Wang H, Franco F, Ho P-C. Metabolic regulation of Tregs in cancer: opportunities for immunotherapy. Trends Cancer. 2017;3:583\u201392. https:\/\/doi.org\/10.1016\/j.trecan.2017.06.005.","journal-title":"Trends Cancer"},{"key":"2487_CR142","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.tips.2019.11.003","volume":"41","author":"Y Liu","year":"2020","unstructured":"Liu Y, Zheng P. Preserving the CTLA-4 checkpoint for safer and more effective cancer immunotherapy. Trends Pharmacol Sci. 2020;41:4\u201312. https:\/\/doi.org\/10.1016\/j.tips.2019.11.003.","journal-title":"Trends Pharmacol Sci"},{"key":"2487_CR143","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/s41590-019-0589-5","volume":"21","author":"H Wang","year":"2020","unstructured":"Wang H, Franco F, Tsui Y-C, Xie X, Trefny MP, Zappasodi R, et al. CD36-mediated metabolic adaptation supports regulatory T cell survival and function in tumors. Nat Immunol. 2020;21:298\u2013308. https:\/\/doi.org\/10.1038\/s41590-019-0589-5.","journal-title":"Nat Immunol"},{"key":"2487_CR144","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1111\/imm.13887","volume":"174","author":"S Dhar","year":"2024","unstructured":"Dhar S, Sarkar T, Bose S, Pati S, Chakraborty D, Roy D, et al. FOXP3 transcriptionally activates fatty acid scavenger receptor CD36 in tumour-induced Treg cells. Immunology. 2024;174:296\u2013309. https:\/\/doi.org\/10.1111\/imm.13887.","journal-title":"Immunology"},{"key":"2487_CR145","doi-asserted-by":"publisher","first-page":"5473","DOI":"10.1158\/0008-5472.CAN-12-1912","volume":"72","author":"JP Hindley","year":"2012","unstructured":"Hindley JP, Jones E, Smart K, Bridgeman H, Lauder SN, Ondondo B, et al. T-cell trafficking facilitated by high endothelial venules is required for tumor control after regulatory T-cell depletion. Cancer Res. 2012;72:5473\u201382. https:\/\/doi.org\/10.1158\/0008-5472.CAN-12-1912.","journal-title":"Cancer Res"},{"key":"2487_CR146","doi-asserted-by":"publisher","unstructured":"Li J, Srivastava RM, Ettyreddy A, Ferris RL. Cetuximab ameliorates suppressive phenotypes of myeloid antigen presenting cells in head and neck cancer patients. J Immunother Cancer. 2015;3:54. https:\/\/doi.org\/10.1186\/s40425-015-0097-6.","DOI":"10.1186\/s40425-015-0097-6"},{"key":"2487_CR147","doi-asserted-by":"publisher","unstructured":"Tian T, Gu X, Zhang B, et al. Increased circulating CD14(+)HLA-DR-\/low myeloid-derived suppressor cells are associated with poor prognosis in patients with small-cell lung cancer. Cancer Biomark. 2015;15(4):425\u201332. https:\/\/doi.org\/10.3233\/CBM-150473.","DOI":"10.3233\/CBM-150473"},{"key":"2487_CR148","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.trecan.2017.11.005","volume":"4","author":"GC Prendergast","year":"2018","unstructured":"Prendergast GC, Mondal A, Dey S, Laury-Kleintop LD, Muller AJ. Inflammatory reprogramming with IDO1 inhibitors: turning immunologically unresponsive cold tumors hot. Trends Cancer. 2018;4:38\u201358. https:\/\/doi.org\/10.1016\/j.trecan.2017.11.005.","journal-title":"Trends Cancer"},{"key":"2487_CR149","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1158\/0008-5472.CAN-14-1491","volume":"75","author":"M Fletcher","year":"2015","unstructured":"Fletcher M, Ramirez ME, Sierra RA, Raber P, Thevenot P, Al-Khami AA, et al. L-arginine depletion blunts antitumor T-cell responses by inducing myeloid-derived suppressor cells. Cancer Res. 2015;75:275\u201383. https:\/\/doi.org\/10.1158\/0008-5472.CAN-14-1491.","journal-title":"Cancer Res"},{"key":"2487_CR150","doi-asserted-by":"publisher","unstructured":"Tumino N, Di Pace AL, Besi F, Quatrini L, Vacca P, Moretta L. Interaction between MDSC and NK cells in solid and hematological malignancies: impact on HSCT. Front Immunol. 2021;12:638841. https:\/\/doi.org\/10.3389\/fimmu.2021.638841.","DOI":"10.3389\/fimmu.2021.638841"},{"key":"2487_CR151","doi-asserted-by":"publisher","first-page":"240","DOI":"10.4049\/jimmunol.182.1.240","volume":"182","author":"H L","year":"2009","unstructured":"L H, H Y, G Q, Z M, C X. Cancer-expanded myeloid-derived suppressor cells induce anergy of NK cells through membrane-bound TGF-beta 1. J Immunol. 2009;182:240\u20139. https:\/\/doi.org\/10.4049\/jimmunol.182.1.240.","journal-title":"J Immunol"},{"key":"2487_CR152","doi-asserted-by":"publisher","first-page":"3723","DOI":"10.3390\/cancers12123723","volume":"12","author":"PM L","year":"2020","unstructured":"L PM, Ca WTA, Jc L, Mr C. The CCR2\/MCP-1 chemokine pathway and lung adenocarcinoma. Cancers. 2020;12:3723. https:\/\/doi.org\/10.3390\/cancers12123723.","journal-title":"Cancers"},{"key":"2487_CR153","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.1007\/s10753-015-0186-1","volume":"38","author":"T Q","year":"2015","unstructured":"Q T. CCR5 Blockade suppresses melanoma development through Inhibition of IL-6-Stat3 pathway via upregulation of SOCS3. Inflammation. 2015;38:2049\u201356. https:\/\/doi.org\/10.1007\/s10753-015-0186-1.","journal-title":"Inflammation"},{"key":"2487_CR154","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1158\/2326-6066.CIR-14-0002","volume":"2","author":"DT Fearon","year":"2014","unstructured":"Fearon DT. The carcinoma-associated fibroblast expressing fibroblast activation protein and escape from immune surveillance. Cancer Immunol Res. 2014;2:187\u201393. https:\/\/doi.org\/10.1158\/2326-6066.CIR-14-0002.","journal-title":"Cancer Immunol Res"},{"key":"2487_CR155","doi-asserted-by":"publisher","first-page":"4558","DOI":"10.1073\/pnas.1815515116","volume":"116","author":"IX Chen","year":"2019","unstructured":"Chen IX, Chauhan VP, Posada J, Ng MR, Wu MW, Adstamongkonkul P, et al. Blocking CXCR4 alleviates desmoplasia, increases T-lymphocyte infiltration, and improves immunotherapy in metastatic breast cancer. Proc Natl Acad Sci U S A. 2019;116:4558\u201366. https:\/\/doi.org\/10.1073\/pnas.1815515116.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2487_CR156","doi-asserted-by":"publisher","first-page":"4769","DOI":"10.1073\/pnas.1900368116","volume":"116","author":"GW Sledge","year":"2019","unstructured":"Sledge GW. Targeting CXCR4-induced desmoplasia to improve checkpoint inhibition in breast cancer. Proc Natl Acad Sci U S A. 2019;116:4769\u201371. https:\/\/doi.org\/10.1073\/pnas.1900368116.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2487_CR157","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-022-05086-z","volume":"13","author":"T Wu","year":"2022","unstructured":"Wu T, Wang W, Shi G, Hao M, Wang Y, Yao M, et al. Targeting HIC1\/TGF-\u03b2 axis-shaped prostate cancer microenvironment restrains its progression. Cell Death Dis. 2022;13:624. https:\/\/doi.org\/10.1038\/s41419-022-05086-z.","journal-title":"Cell Death Dis"},{"key":"2487_CR158","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1007\/s10456-022-09863-4","volume":"26","author":"P Nowak-Sliwinska","year":"2022","unstructured":"Nowak-Sliwinska P, van Beijnum JR, Griffioen CJ, Huinen ZR, Sopesens NG, Schulz R, et al. Proinflammatory activity of VEGF-targeted treatment through reversal of tumor endothelial cell anergy. Angiogenesis. 2022;26:279\u201393. https:\/\/doi.org\/10.1007\/s10456-022-09863-4.","journal-title":"Angiogenesis"},{"key":"2487_CR159","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aak9679","volume":"9","author":"E Allen","year":"2017","unstructured":"Allen E, Jabouille A, Rivera LB, Lodewijckx I, Missiaen R, Steri V, et al. Combined antiangiogenic and anti-PD-L1 therapy stimulates tumor immunity through HEV formation. Sci Transl Med. 2017;9:eaak9679. https:\/\/doi.org\/10.1126\/scitranslmed.aak9679.","journal-title":"Sci Transl Med"},{"issue":"4","key":"2487_CR160","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1002\/hep.30889","volume":"71","author":"K Shigeta","year":"2019","unstructured":"Shigeta K, Datta M, Hato T, Kitahara S, Chen IX, Matsui A, et al. Dual programmed death receptor-1 and vascular endothelial growth factor receptor-2 blockade promotes vascular normalization and enhances antitumor immune responses in hepatocellular carcinoma. Hepatology. 2019;71(4):1247\u201361. https:\/\/doi.org\/10.1002\/hep.30889.","journal-title":"Hepatology"},{"key":"2487_CR161","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2021.102192","volume":"97","author":"IA Vathiotis","year":"2021","unstructured":"Vathiotis IA, Johnson JM, Argiris A. Enhancing programmed cell death protein 1 axis inhibition in head and neck squamous cell carcinoma: combination immunotherapy. Cancer Treat Rev. 2021;97:102192. https:\/\/doi.org\/10.1016\/j.ctrv.2021.102192.","journal-title":"Cancer Treat Rev"},{"key":"2487_CR162","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-016-0165-6","volume":"4","author":"SE Stanton","year":"2016","unstructured":"Stanton SE, Disis ML. Clinical significance of tumor-infiltrating lymphocytes in breast cancer. J Immunother Cancer. 2016;4:59. https:\/\/doi.org\/10.1186\/s40425-016-0165-6.","journal-title":"J Immunother Cancer"},{"key":"2487_CR163","doi-asserted-by":"publisher","first-page":"5193","DOI":"10.1158\/1078-0432.CCR-18-1475","volume":"24","author":"G Pawelec","year":"2018","unstructured":"Pawelec G. Unexpected benefits of aging for favorable responses to PD-1 blockade in melanoma? Clin Cancer Res. 2018;24:5193\u20134. https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-1475.","journal-title":"Clin Cancer Res"},{"key":"2487_CR164","doi-asserted-by":"publisher","first-page":"517","DOI":"10.6004\/jnccn.2020.7543","volume":"18","author":"S Chumsri","year":"2020","unstructured":"Chumsri S, Sokol ES, Soyano-Muller AE, Parrondo RD, Reynolds GA, Nassar A, et al. Durable complete response with immune checkpoint inhibitor in breast cancer with high tumor mutational burden and APOBEC signature. J Natl Compr Canc Netw. 2020;18:517\u201321. https:\/\/doi.org\/10.6004\/jnccn.2020.7543.","journal-title":"J Natl Compr Canc Netw"},{"key":"2487_CR165","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.ccell.2019.08.009","volume":"36","author":"MK Callahan","year":"2019","unstructured":"Callahan MK, Wolchok JD. Recruit or reboot? How does anti-PD-1 therapy change tumor-infiltrating lymphocytes? Cancer Cell. 2019;36:215\u20137. https:\/\/doi.org\/10.1016\/j.ccell.2019.08.009.","journal-title":"Cancer Cell"},{"key":"2487_CR166","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1016\/j.ccell.2019.10.009","volume":"36","author":"A Trinh","year":"2019","unstructured":"Trinh A, Polyak K. Tumor neoantigens: when too much of a good thing is bad. Cancer Cell. 2019;36:466\u20137. https:\/\/doi.org\/10.1016\/j.ccell.2019.10.009.","journal-title":"Cancer Cell"},{"key":"2487_CR167","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1053\/j.gastro.2020.11.041","volume":"160","author":"V Matson","year":"2021","unstructured":"Matson V, Chervin CS, Gajewski TF. Cancer and the microbiome-influence of the commensal microbiota on cancer, immune responses, and immunotherapy. Gastroenterology. 2021;160:600\u201313. https:\/\/doi.org\/10.1053\/j.gastro.2020.11.041.","journal-title":"Gastroenterology"},{"issue":"1","key":"2487_CR168","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s13045-018-0592-6","volume":"11","author":"M Yi","year":"2018","unstructured":"Yi M, Yu S, Qin S, Liu Q, Xu H, Zhao W, et al. Gut microbiome modulates efficacy of immune checkpoint inhibitors. J Hematol Oncol. 2018;11:47. https:\/\/doi.org\/10.1186\/s13045-018-0592-6.","journal-title":"J Hematol Oncol"},{"key":"2487_CR169","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14010046","volume":"14","author":"M Mets\u00e4niitty","year":"2021","unstructured":"Mets\u00e4niitty M, Hasnat S, Salo T, Salem A. Oral microbiota-a new frontier in the pathogenesis and management of head and neck cancers. Cancers. 2021;14:46. https:\/\/doi.org\/10.3390\/cancers14010046.","journal-title":"Cancers"},{"key":"2487_CR170","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14174116","volume":"14","author":"KM Burcher","year":"2022","unstructured":"Burcher KM, Burcher JT, Inscore L, Bloomer CH, Furdui CM, Porosnicu M. A review of the role of oral microbiome in the development, detection, and management of head and neck squamous cell cancers. Cancers. 2022;14:4116. https:\/\/doi.org\/10.3390\/cancers14174116.","journal-title":"Cancers"},{"key":"2487_CR171","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12113425","volume":"12","author":"Z Chen","year":"2020","unstructured":"Chen Z, Wong PY, Ng CWK, Lan L, Fung S, Li JW, et al. The intersection between oral microbiota, host gene methylation and patient outcomes in head and neck squamous cell carcinoma. Cancers. 2020;12:3425. https:\/\/doi.org\/10.3390\/cancers12113425.","journal-title":"Cancers"},{"key":"2487_CR172","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2024.1369834","volume":"15","author":"L Su","year":"2024","unstructured":"Su L, Yang R, Sheng Y, Ullah S, Zhao Y, Shunjiayi H, et al. Insights into the oral microbiota in human systemic cancers. Front Microbiol. 2024;15:1369834. https:\/\/doi.org\/10.3389\/fmicb.2024.1369834.","journal-title":"Front Microbiol"},{"key":"2487_CR173","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1177\/00220345241262759","volume":"103","author":"XX Wang","year":"2024","unstructured":"Wang XX, Liu YT, Ren JG, Liu HM, Fu Q, Yang Y, et al. Salivary microbiome relates to neoadjuvant immunotherapy response in OSCC. J Dent Res. 2024;103:988\u201398. https:\/\/doi.org\/10.1177\/00220345241262759.","journal-title":"J Dent Res"},{"key":"2487_CR174","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-023-10532-y","volume":"23","author":"Y Ding","year":"2023","unstructured":"Ding Y, Chu L, Cao Q, Lei H, Li X, Zhuang Q. A meta-validated immune infiltration-related gene model predicts prognosis and immunotherapy sensitivity in HNSCC. BMC Cancer. 2023;23:45. https:\/\/doi.org\/10.1186\/s12885-023-10532-y.","journal-title":"BMC Cancer"},{"key":"2487_CR175","doi-asserted-by":"publisher","first-page":"3813","DOI":"10.1172\/JCI99760","volume":"128","author":"S Goswami","year":"2018","unstructured":"Goswami S, Apostolou I, Zhang J, Skepner J, Anandhan S, Zhang X, et al. Modulation of EZH2 expression in T cells improves efficacy of anti-CTLA-4 therapy. J Clin Invest. 2018;128:3813\u20138. https:\/\/doi.org\/10.1172\/JCI99760.","journal-title":"J Clin Invest"},{"key":"2487_CR176","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2017.1315486","volume":"6","author":"CA Carter","year":"2017","unstructured":"Carter CA, Oronsky BT, Roswarski J, Oronsky AL, Oronsky N, Scicinski J, et al. No patient left behind: the promise of immune priming with epigenetic agents. Oncoimmunology. 2017;6:e1315486. https:\/\/doi.org\/10.1080\/2162402X.2017.1315486.","journal-title":"Oncoimmunology"},{"key":"2487_CR177","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1038\/s41568-019-0109-9","volume":"19","author":"PA Jones","year":"2019","unstructured":"Jones PA, Ohtani H, Chakravarthy A, De Carvalho DD. Epigenetic therapy in immune-oncology. Nat Rev Cancer. 2019;19:151\u201361. https:\/\/doi.org\/10.1038\/s41568-019-0109-9.","journal-title":"Nat Rev Cancer"},{"key":"2487_CR178","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2024.217095","volume":"598","author":"L-M Cao","year":"2024","unstructured":"Cao L-M, Zhong N-N, Chen Y, Li Z-Z, Wang G-R, Xiao Y, et al. Less is more: exploring neoadjuvant immunotherapy as a de-escalation strategy in head and neck squamous cell carcinoma treatment. Cancer Lett. 2024;598:217095. https:\/\/doi.org\/10.1016\/j.canlet.2024.217095.","journal-title":"Cancer Lett"},{"key":"2487_CR179","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2023.102644","volume":"121","author":"D Smussi","year":"2023","unstructured":"Smussi D, Mattavelli D, Paderno A, Gurizzan C, Lorini L, Romani C, et al. Revisiting the concept of neoadjuvant and induction therapy in head and neck cancer with the advent of immunotherapy. Cancer Treat Rev. 2023;121:102644. https:\/\/doi.org\/10.1016\/j.ctrv.2023.102644.","journal-title":"Cancer Treat Rev"},{"key":"2487_CR180","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-019-0787-5","volume":"12","author":"T Jiang","year":"2019","unstructured":"Jiang T, Shi T, Zhang H, Hu J, Song Y, Wei J, et al. Tumor neoantigens: from basic research to clinical applications. J Hematol Oncol. 2019;12:93. https:\/\/doi.org\/10.1186\/s13045-019-0787-5.","journal-title":"J Hematol Oncol"},{"key":"2487_CR181","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/s41586-018-0792-9","volume":"565","author":"DB Keskin","year":"2018","unstructured":"Keskin DB, Anandappa AJ, Sun J, Tirosh I, Mathewson ND, Li S, et al. Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial. Nature. 2018;565:234\u20139. https:\/\/doi.org\/10.1038\/s41586-018-0792-9.","journal-title":"Nature"},{"key":"2487_CR182","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-021-01335-5","volume":"20","author":"L Miao","year":"2021","unstructured":"Miao L, Zhang Y, Huang L. mRNA vaccine for cancer immunotherapy. Mol Cancer. 2021;20:41. https:\/\/doi.org\/10.1186\/s12943-021-01335-5.","journal-title":"Mol Cancer"},{"key":"2487_CR183","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adn9961","volume":"10","author":"T Fan","year":"2024","unstructured":"Fan T, Xu C, Wu J, Cai Y, Cao W, Shen H, et al. Lipopolyplex-formulated mRNA cancer vaccine elicits strong neoantigen-specific T cell responses and antitumor activity. Sci Adv. 2024;10:eadn9961. https:\/\/doi.org\/10.1126\/sciadv.adn9961.","journal-title":"Sci Adv"},{"key":"2487_CR184","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/S0140-6736(23)02268-7","volume":"403","author":"JS Weber","year":"2024","unstructured":"Weber JS, Carlino MS, Khattak A, Meniawy T, Ansstas G, Taylor MH, et al. Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study. Lancet. 2024;403:632\u201344. https:\/\/doi.org\/10.1016\/S0140-6736(23)02268-7.","journal-title":"Lancet"}],"container-title":["Molecular Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-025-02487-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12943-025-02487-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-025-02487-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T18:16:38Z","timestamp":1762884998000},"score":1,"resource":{"primary":{"URL":"https:\/\/molecular-cancer.biomedcentral.com\/articles\/10.1186\/s12943-025-02487-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,10]]},"references-count":184,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2487"],"URL":"https:\/\/doi.org\/10.1186\/s12943-025-02487-4","relation":{},"ISSN":["1476-4598"],"issn-type":[{"value":"1476-4598","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,10]]},"assertion":[{"value":"18 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"284"}}